Ridgefield, CT, United States of America

Gary Gustafson

USPTO Granted Patents = 44 

 

 

Average Co-Inventor Count = 8.2

ph-index = 13

Forward Citations = 415(Granted Patents)


Company Filing History:


Years Active: 2009-2025

Loading Chart...
Loading Chart...
Loading Chart...
44 patents (USPTO):

Title: Innovations in Hemoglobin Treatments: The Contributions of Gary Gustafson

Introduction: Gary Gustafson, an accomplished inventor based in Ridgefield, CT, has made significant strides in the field of biotechnology, particularly through his groundbreaking research and innovations. With an impressive portfolio of 43 patents, his work focuses on enhancing hemoglobin's affinity for oxygen, paving the way for new treatments for hemoglobinopathies.

Latest Patents: Among Gustafson's most recent patents is the activation of pyruvate kinase R, which details a compound named (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroxy-2-phenylpropan-1-one. This compound, or a pharmaceutically acceptable salt thereof, holds promise for increasing the affinity of hemoglobin for oxygen. Additionally, he has developed methods and compositions that provide novel therapeutic avenues for treating hemoglobinopathies, including pharmaceutical compositions aimed at activating PKR. His patents also encompass new chemical compounds that serve as activators of PKR, which are useful in addressing diseases associated with the modulation of PKR and PKM2, particularly pyruvate kinase deficiency (PKD).

Career Highlights: Gary Gustafson has built a distinguished career by contributing to various innovative solutions in the biotechnology sector. His expertise and inventions have placed him at the forefront of medical research, particularly in improving treatments surrounding hemoglobin-related disorders. His patents not only reflect his inventive spirit but also stand as invaluable assets in the pharmaceutical industry.

Collaborations: Throughout his career, Gustafson has collaborated with notable professionals, including David R. Lancia, Jr. and Zhongguo Wang. These partnerships have facilitated the exchange of ideas and fostered advances in their shared research interests, ultimately leading to significant discoveries and developments in their field.

Conclusion: Gary Gustafson's innovative contributions and collaborative efforts position him as a prominent figure in the realm of biotechnology. His 43 patents demonstrate a commitment to exploring and creating solutions for complex health issues. As he continues to advance research in activating pyruvate kinase R and other related areas, Gustafson's impact on medical science will undoubtedly grow, offering hope for improved treatments for individuals with hemoglobinopathies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…